GH Research (NASDAQ:GHRS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS - Free Report) in a research report released on Friday,Benzinga reports. They currently have a $40.00 price objective on the stock.

A number of other brokerages have also commented on GHRS. Cantor Fitzgerald assumed coverage on shares of GH Research in a research report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price objective for the company. Guggenheim began coverage on GH Research in a report on Thursday, March 13th. They issued a "buy" rating and a $32.00 price target for the company. Stifel Nicolaus raised their price objective on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, Royal Bank of Canada assumed coverage on GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $30.43.

GH Research Trading Down 3.5%

GHRS traded down $0.38 during midday trading on Friday, reaching $10.42. The company's stock had a trading volume of 70,405 shares, compared to its average volume of 176,277. The company has a fifty day simple moving average of $10.31 and a 200 day simple moving average of $9.87. The stock has a market cap of $542.13 million, a P/E ratio of -13.19 and a beta of 0.86. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.42. Sell-side analysts expect that GH Research will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

Institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new position in shares of GH Research during the 1st quarter worth approximately $8,272,000. Lynx1 Capital Management LP raised its stake in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Diadema Partners LP bought a new position in shares of GH Research during the fourth quarter valued at $711,000. Woodline Partners LP boosted its stake in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after purchasing an additional 41,711 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of GH Research in the 4th quarter worth about $145,000. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).